Clinical Trial

CKM Syndrome Prevalence and Its Association With SCORE-2 and BRI

Study acronym: CKM-PREV
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 25, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This cross-sectional study aims to determine the prevalence of Cardiovascular-Kidney-Metabolic (CKM) syndrome in a community-based adult population in Gaziantep, Türkiye. In addition to estimating the prevalence across CKM stages, the study investigates the associations between CKM syndrome and two key risk indicators: the SCORE-2 cardiovascular risk score and Body Roundness Index (BRI). Findings from this study will provide valuable insights into early cardiometabolic risk profiling and support the development of regionally tailored prevention strategies.
Trial Details
NCT Number NCT06944236
Lead Sponsor University of Gaziantep
Conditions Metabolic Syndrome, Cardiovascular Diseases, Chronic Kidney Disease(CKD)
Enrollment 400 participants
Start Date 2025-06-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-25